Pregnancy: a risk factor for Budd-Chiari syndrome?

Rautou, P.-E.; Plessier, A.; Bernuau, J.; Denninger, M.-H.; Moucari, R.; Valla, D.
April 2009
Gut;Apr2009, Vol. 58 Issue 4, p606
Academic Journal
The article reports on a study conducted to determine whether multiple thrombotic risks factors are present in patients with Budd-Chiari syndrome (BCS). It notes that due to the basis of an increased risk of BCS among oral contraceptive users, an influence of female sex hormones on the risk of BCS has long been recognized. It shows that 43 out of 96 women with primary BCS diagnosed in the center between January 1995 and December 2005 aged 15-45 years at diagnosis.


Related Articles

  • questionable contraception. Martin, Adam // Health (Time Inc. Health);Sep2003, Vol. 17 Issue 7, p74 

    Discusses the results of a survey of French women who got pregnant unintentionally. Percentage of the respondents who were using contraceptives; Birth control methods used; Duration of high-dose oral contraceptives.

  • Long-term OC use may increase miscarriage risk.  // Reactions Weekly;8/20/2005, Issue 1065, p3 

    Reports on the link between long-term use of oral contraceptives (OC) and increased risk of miscarriage according to the results of a case-control study. Odds ratio for miscarriage for patients who had taken OC for twenty four months prior to pregnancy; Ages of women susceptible to miscarriage.

  • Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Kemmeren, Jeanet M; Algra, Ale; Grobbee, Diederick E // BMJ: British Medical Journal (International Edition);7/21/2001, Vol. 323 Issue 7305, Special section p1 

    Results: The overall adjusted odds ratio for third versus second generation oral contraceptives was 1.7 (95% confidence interval 1.4 to 2.0; seven studies). Similar risks were found when oral contraceptives containing desogestrel or gestodene were compared with those containing levonorgestrel....

  • Male sex, first idiopathic deep venous thrombosis, and oral contraception were risk factors for recurrent venous thrombotic events. Christiansen, S. C.; Cannegieter, S. C.; Koster, T. // Evidence Based Medicine;Apr2006, Vol. 11 Issue 2, p59 

    The article reports focuses on a study on the contribution of male gender, first idiopathic deep venous thrombosis and oral contraception on the occurrence of recurrent venous thrombotic events. Prothrombotic abnormalities however did not appear to play an important role. The study was conducted...

  • etonogestrel.  // Royal Society of Medicine: Medicines;2002, p237 

    This article focuses on progestogen etonogestrel. It is used as an oral contraceptive in the form of implant.

  • Marvelon.  // Royal Society of Medicine: Medicines;2002, p347 

    This article presents information on Marvelon, a proprietary, prescription-only compound preparation than can be used as oral contraceptives of the COC type that combines an estrogen and progesterone, in this case ethinylestradiol and desogestrel. It is available as tablets.

  • TriNovum.  // Royal Society of Medicine: Medicines;2002, p549 

    The article provides information on trinovum which can be used as an oral contraceptive of the combined oral contraceptive type that combines an oestrogen and a progestogen. It is available as tablets in a calendar pack.

  • Estrogen and Thromboembolic Disorders: Should Patients Stop Hormones Prior to Cosmetic Surgery? Shiffman, Melvin A. // Journal of Women's Health (15409996);Nov2003, Vol. 12 Issue 9, p853 

    Oral contraceptives and replacement estrogenic hormones have been associated with a significant risk of thromboembolism. Cosmetic surgery consists of elective procedures in otherwise healthy individuals. The prospect of thromboembolism should be diminished in these patients by avoiding those...

  • New Study Casts Doubts on the Association Between Third-Generation Pills and Venous Thromboembolism. O'Connor, M.L. // Family Planning Perspectives;Jul/Aug97, Vol. 29 Issue 4, p192 

    This article reports on the link between venous thromboembolism and oral contraceptives containing the "third-generation" progestogens gestodene and desogestrel which may not be as strong as has been suggested, according to a study conducted in the United Kingdom. While a cohort analysis showed...


Read the Article


Sign out of this library

Other Topics